<DOC>
	<DOC>NCT01854047</DOC>
	<brief_summary>Primary Objective: To evaluate the efficacy of different doses and regimens of dupilumab in patients with moderate to severe uncontrolled asthma Secondary Objective: To evaluate different doses and regimens of dupilumab in patients with moderate to severe uncontrolled asthma, with regard to: - Safety and tolerability - Dupilumab systemic exposure and anti-drug antibodies</brief_summary>
	<brief_title>An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma</brief_title>
	<detailed_description>Total duration per participant of approximately 43 weeks including a screening period (14-21 days) , a randomized treatment period (24 weeks), and a post-treatment period (16 weeks).</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Inclusion criteria: Patients with a physician diagnosis of moderate to severe, uncontrolled asthma for ≥12 months, based on the Global Initiative for Asthma (GINA) 2009 Guidelines and: Existing treatment with moderate or highdose inhaled corticosteroid / longacting beta2 agonist Forced expiratory volume (FEV1) 40 to 80% of predicted normal Juniper Asthma Control Questionnaire, 5question version (ACQ5) score ≥1.5 Reversibility of at least 12% and 200 mL in forced expiratory volume (FEV1) Has experienced, within prior year: hospitalization, emergency or urgent care visit or systemic corticosteroid treatment for worsening asthma Exclusion criteria: Patients &lt;18 years Chronic obstructive pulmonary disease (COPD) or other lung diseases (eg, emphysema, idiopathic pulmonary fibrosis, ChurgStrauss syndrome, allergic bronchopulmonary aspergillosis) which impair pulmonary function tests Chest Xray within 12 months of screening visit or at screening visit with clinically significant findings of lung disease(s) other than asthma Current smoker or cessation of smoking within 6 months prior to Visit 1 Previous smoker with a smoking history &gt;10 packyears The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>